Skip to main content

Table 1 Demographic and baseline characteristics

From: Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community

Variable

Overall N = 118

Buprenorphine N = 68

Methadone N = 50

Gender—N (%)

 Woman

32 (27.12%)

21 (30.88%)

11 (22.00%)

 Man

86 (72.88%)

47 (69.12%)

39 (78.00%)

Race N (%)

 White

69 (58.47%)

36 (52.94%)

33 (66.00%)

 Black/African American

29 (24.58%)

19 (27.94%)

10 (20.00%)

 Other

10 (8.47%)

6 (8.82%)

4 (8.00%)

 More than one race

6 (5.08%)

5 (7.35%)

1 (2.00%)

 Native American

4 (3.39%)

2 (2.94%)

2 (4.00%)

Hispanic or Latinx N (%)

37 (31.36%)

27 (39.71%)

10 (20.00%)

Age—mean (SD)

42.41 (12.64)

44.12 (12.04)

40.08 (13.19)

Education—HS equivalent or greater—N (%)

93 (78.81%)

51 (75.00%)

42 (84.00%)

Pain interference—mean (SD)

2.55 (1.28)

2.72 (1.35)

2.32 (1.15)

Transportation satisfaction—mean (SD)

3.12 (1.27)

3.03 (1.27)

3.24 (1.27)

High dose of MOUDa—N (%)

59 (50.00%)

38 (55.88%)

21 (42.00%)

Six-month MOUD retention—N (%)

62 (52.54%)

33 (48.53%)

29 (58.00%)

Houseless—N (%)

38 (32.20%)

25 (36.76%)

13 (26.00%)

Working in past 30 days—N (%)

24 (20.34%)

15 (22.06%)

9 (18.00%)

Insurance coverage in prior 30 days—N (%)

116 (98.31%)

68 (100.00%)

48 (96.00%)

Referred from carceral setting (prison or jail)

19 (16.10%)

10 (14.71%)

9 (18.00%)

Living with HIV—N (%)

43 (36.44%)

32 (47.06%)

11 (22.00%)

MINI Major Depressive Disorder, current—N (%)

31 (28.18%)

18 (27.69%)

13 (28.89%)

MINI Major Depressive Disorder, past—N (%)

45 (40.91%)

27 (41.54%)

18 (40.00%)

WHOQoL BREF Physical—mean (SD)

13.09 (3.59)

13.04 (3.73)

13.15 (3.44)

WHOQoL BREF Psychological—mean (SD)

13.42 (3.34)

13.61 (3.30)

13.18 (3.41)

WHOQoL BREF Social Relationships—mean (SD)

13.38 (3.77)

13.53 (3.81)

13.17 (3.74)

WHOQoL BREF Environment—mean (SD)

13.30 (2.88)

13.10 (2.82)

13.57 (2.97)

Opioid Craving Scale—Mean (SD)

6.85 (3.47)

6.41 (3.72)

7.44 (3.02)

ASSIST Any Cocaine use, past 3 months—N (%)

 No

63 (53.39%)

40 (58.82%)

23 (46.00%)

 Yes

55 (46.61%)

28 (41.18%)

27 (54.00%)

  1. MOUD medications for opioid use disorder; MINI Mini International Neuropsychiatric Interview; WHOQoL BREF World Health Organization Quality of Life, 26 item version; ASSIST Smoking and Substance Involvement Screening Test
  2. aHigh dose of MOUD defined as methadone dose > 85 mg or buprenorphine dose ≥ 16 mg: